Physician profile
John Robert Velky
NPI 1659307593
$14,041.55
in general payments reported to CMS, 2019-2025
64 companies · $2,408 in 2025
The $2,408 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,489 · 2020: $419 · 2021: $1,427 · 2022: $2,186 · 2023: $2,682 · 2024: $2,432 · 2025: $2,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,520.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,727.85 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,547.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,221.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,185.34 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,091.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $992.71 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $484.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $421.70 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.96 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.65 | 2019-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $322.01 | 2022-2025 | Rexulti |
| Amgen INC. | $309.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $238.04 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $230.43 | 2022 | |
| Merck Sharp & Dohme LLC | $217.52 | 2019-2021 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Velky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.